pISSN 2234-3806
eISSN 2234-3814

Table. 3.

Table 3 Consideration points for clinical pharmacogenetic testing

Characteristics of drugs for which clinical pharmacogenetic testing may be considered [43]
Significant inter-individual variability in drug response Narrow therapeutic range Potential for severe adverse effects Development of treatment resistance Need for long-term treatment High cost of the medication

Characteristics of drugs for which clinical pharmacogenetic testing may be considered [43]

Significant inter-individual variability in drug response

Narrow therapeutic range

Potential for severe adverse effects

Development of treatment resistance

Need for long-term treatment

High cost of the medication

Consideration points for clinical pharmacogenetic testing
Correlation between genotype and phenotype (predictive power for drug response)	The degree of correlation between genetic variants and drug response outcomes should be well established.
Clear and sufficient evidence of clinical utility	There must be robust evidence supporting the clinical usefulness of pharmacogenetic testing, such as large-scale studies, randomized controlled trials, and meta-analyses.
Standardized guidelines for drug selection and dosage adjustment based on pharmacogenetic profiles	There should be clear, standardized guidelines on how to use pharmacogenomic information to select drugs and adjust dosages.
Genotypic and phenotypic variability by ethnicity or race	Information on the types and distribution of alleles and genotypes across different ethnic or racial groups should be available.
Technical feasibility and analytical capability of testing methods	The ease of use, expected analytical performance, and cost of testing should be considered.
Comprehensive interpretation by experts	The ability to provide thorough result interpretation should be supported by adequate knowledge and experience in various fields, such as medicine, clinical pharmacology, clinical genetics, and laboratory medicine.
Turnaround time for results	The time required to obtain test results should align with the clinical indications and requirements of the healthcare environment.
Cost-effectiveness	The clinical utility of the test should justify its cost, with a favorable balance between test expenses and the benefits gained.

Ann Lab Med 2025;45:121~132 https://doi.org/10.3343/alm.2024.0572